Incomplete radiochemotherapeutic treatment responses and poorer cancer-related survivals occur if human papilloma virus (HPV) and abnormal p53 signaling overactivates ribonucleotide reductase in cancers of the uterine cervix (1–8). The gene discussed is TP53; the disease is cervical cancer.